Qiagen (NYSE:QGEN) Given Equal Weight Rating at Morgan Stanley

Qiagen (NYSE:QGEN)‘s stock had its “equal weight” rating reaffirmed by research analysts at Morgan Stanley in a report issued on Monday,Benzinga reports. They presently have a $48.00 price objective on the stock, down from their previous price objective of $50.00. Morgan Stanley’s target price points to a potential upside of 6.74% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research note on Thursday, October 17th. Jefferies Financial Group reiterated a “buy” rating and set a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Qiagen currently has an average rating of “Moderate Buy” and a consensus price target of $51.50.

Qiagen Stock Up 1.0 %

QGEN opened at $44.97 on Monday. The stock has a market capitalization of $10.26 billion, a P/E ratio of 115.31, a price-to-earnings-growth ratio of 3.52 and a beta of 0.37. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a one year low of $39.03 and a one year high of $47.44. The business’s 50-day simple moving average is $43.75 and its 200-day simple moving average is $43.82.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Qiagen by 170.1% during the 4th quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock worth $68,000 after purchasing an additional 956 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Qiagen by 36.0% in the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after buying an additional 424,937 shares in the last quarter. Tidal Investments LLC acquired a new position in Qiagen during the third quarter worth $490,000. Wilmington Savings Fund Society FSB purchased a new position in Qiagen in the third quarter worth $53,000. Finally, Sanctuary Advisors LLC lifted its holdings in Qiagen by 24.8% in the third quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock valued at $834,000 after acquiring an additional 3,878 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.